Datasheet for ABIN988151

CXCL9 Protein

Go to Product page

Overview

Quantity:	1 mg
Target:	CXCL9
Origin:	Human
Source:	Escherichia coli (E. coli)
Biological Activity:	Active

Product Details

Sequence:	TPVVRKGRCS CISTNQGTIH LQSLKDLKQF APSPSCEKIE IIATLKNGVQ TCLNPDSADV KELIKKWEKQ VSQKKKQKNG KKHQKKKVLK VRKSQRSRQK KT
Characteristics:	Fully biologically active when compared to standard. The ED50 determined by a chemotaxis bioassay using human peripheral blood T-lymphocytes is less than 100 ng/ml, corresponding to a specific activity of >, 1.0 × 104 IU/mg.
Purity:	> 97 % by SDS-PAGE and HPLC analyses.
Endotoxin Level:	Level Less than 1EU/μg of rHuMIG/CXCL9 as determined by LAL method

Target Details

Target:	CXCL9
Alternative Name:	MIG/CXCL9 (CXCL9 Products)
Background:	CXCL9, a member of the ª subfamily of chemokines that lack the ELR domain, was initially identified as a lymphokine-activated gene in mouse macrophages. The CXCL9 gene is induced in macrophages and in primary glial cells of the central nervous system specifically in response

Target Details

	to IFN-Î³. CXCL9 has been shown to be a chemoattractant for activated T-lymphocytes and TIL but not for neutrophils or monocytes. The human CXCL9 cDNA encodes a 125 amino acid residue precursor protein with a 22 amino acid residue signal peptide that is cleaved to yield a 103 amino acid residue mature protein. CXCL9 has an extended carboxy-terminus containing greater than 50% basic amino acid residues and is larger than most other chemokines. A chemokine receptor (CXCR3) specific for CXCL9 and IP-10 has recently been cloned and shown to be highly expressed in IL-2-activated T-lymphocytes. Synonym: MIG/CXCL9, Human. Formulation: Lyophilized from a 0.2µm filtered concentrated solution in 20mM PB, pH 7.4, 50mM NaCl.
Molecular Weight:	11.7 kDa, a single non-glycosylated polypeptide chain containing 103 amino acids.

Application Details

Restrictions:	For Research Use only

Handling

Format:	Lyophilized
Reconstitution:	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at < -20 °C. Further dilutions should be made in appropriate buffered solutions.
Storage:	4 °C